首页> 美国卫生研究院文献>High-Throughput >Immune-Signatures for Lung Cancer Diagnostics: Evaluation of Protein Microarray Data Normalization Strategies
【2h】

Immune-Signatures for Lung Cancer Diagnostics: Evaluation of Protein Microarray Data Normalization Strategies

机译:肺癌诊断的免疫签名:蛋白质芯片数据归一化策略的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

New minimal invasive diagnostic methods for early detection of lung cancer are urgently needed. It is known that the immune system responds to tumors with production of tumor-autoantibodies. Protein microarrays are a suitable highly multiplexed platform for identification of autoantibody signatures against tumor-associated antigens (TAA). These microarrays can be probed using 0.1 mg immunoglobulin G (IgG), purified from 10 µL of plasma. We used a microarray comprising recombinant proteins derived from 15,417 cDNA clones for the screening of 100 lung cancer samples, including 25 samples of each main histological entity of lung cancer, and 100 controls. Since this number of samples cannot be processed at once, the resulting data showed non-biological variances due to “batch effects”. Our aim was to evaluate quantile normalization, “distance-weighted discrimination” (DWD), and “ComBat” for their effectiveness in data pre-processing for elucidating diagnostic immune-signatures. “ComBat” data adjustment outperformed the other methods and allowed us to identify classifiers for all lung cancer cases versus controls and small-cell, squamous cell, large-cell, and adenocarcinoma of the lung with an accuracy of 85%, 94%, 96%, 92%, and 83% (sensitivity of 0.85, 0.92, 0.96, 0.88, 0.83; specificity of 0.85, 0.96, 0.96, 0.96, 0.83), respectively. These promising data would be the basis for further validation using targeted autoantibody tests.
机译:迫切需要用于肺癌早期发现的新的微创诊断方法。已知免疫系统对肿瘤的反应是产生肿瘤自身抗体。蛋白质微阵列是用于鉴定针对肿瘤相关抗原(TAA)的自身抗体签名的合适的高度复用平台。可以使用从10 µL血浆中纯化的0.1 mg免疫球蛋白G(IgG)探测这些微阵列。我们使用了一种微阵列,该微阵列包含来自15,417个cDNA克隆的重组蛋白,用于筛选100个肺癌样品,包括肺癌每个主要组织学实体的25个样品和100个对照。由于无法同时处理此数量的样本,因此由于“批处理效应”,所得数据显示出非生物差异。我们的目的是评估分位数归一化,“距离加权歧视”(DWD)和“ ComBat”在数据预处理中阐明诊断性免疫特征的有效性。 “ ComBat”数据调整优于其他方法,使我们能够识别所有肺癌病例与对照以及肺小细胞,鳞状细胞,大细胞和腺癌的分类器,准确度分别为85%,94%,96分别为%,92%和83%(灵敏度为0.85、0.92、0.96、0.88、0.83;特异性为0.85、0.96、0.96、0.96、0.83)。这些有希望的数据将成为使用靶向自身抗体测试进行进一步验证的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号